AI can reduce R&D costs to alleviate looming patent cliff pressures
AI will be a useful tool in reducing R&D costs to help alleviate some of the pain pharma will feel…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints
Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell…
-
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium chloride) after…
-
UK patients being “denied access to cutting-edge clinical research”
UK patients are being “denied the opportunity to participate in cutting-edge clinical research”, according to the Association of the British…
-
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
Mabwell Bioscience’s anti-ST2 monoclonal antibody (mAb) has led to a 40% reduction in annualised severe exacerbations in patients with chronic…
-
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
The US Food and Drug Administration’s (FDA’s) new pathway for gene therapies could be “groundbreaking” if applied broadly, though the…
-
Zhongmou Therapeutics’ RP gene therapy shows promise in first-in-human trial
Zhongmou Therapeutics’ gene therapy for advanced retinitis pigmentosa (RP) has shown promise in a first-in-human trial. In the MOON study…
-
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs
Sarepta Therapeutics will be investigating the potential of using an immunosuppressant both before and after treatment with Elevidys (delandistrogene moxeparvovec-rokl)…
-
Enlivex’s allogeneic cell therapy benefit continues at six months
Enlivex Therapeutics’ off-the-shelf cell therapy has shown six-month success in patients with moderate to severe knee osteoarthritis (KOA). In the…
-
Sarepta terminates Hansa-partnered gene therapy combination trial
Sarepta Therapeutics has terminated a Phase I trial evaluating its gene therapy Elevidys (delandistrogene moxeparvovec) in combination with Hansa Biopharma’s…